For example, evERA BC (NCT05306340) is a global, randomized phase III study comparing the oral SERD giredestrant plus everolimus versus exemestane plus everolimus in patients with HR+/HER2− ABC previously treated with endocrine therapy and a CDK4/6 inhibitor (n = 320) [78]. The gene discussed is CDK4; the disease is breast cancer.